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PCONGENITAL HEART DISEASE
Anemia in Adults With Congenital Heart Disease
Relates to Adverse Outcome
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London, United Kingdom
Objectives To assess the relation of anemia in noncyanotic adults with congenital heart disease (ACHD) to functional capac-
ity and mortality.
Background Anemia is common in acquired heart failure and affects prognosis. The presence of anemia and its relation to
outcome in ACHD remain unknown.
Methods Data were collected on consecutive noncyanotic ACHD patients attending our tertiary center between 2001 and
2006 in whom hemoglobin concentration was measured. Anemia was defined as hemoglobin concentration
13 g/dl in males and 12 g/dl in females. Cyanotic patients were excluded to avoid confounding from sec-
ondary erythrocytosis.
Results Overall, 830 noncyanotic ACHD patients (age 36.5  15.0 years, 49.6% male) fulfilled the inclusion criteria. The
prevalence of anemia was 13.1% and was highest in patients with congenitally corrected transposition of great
arteries and Ebstein anomaly of the tricuspid valve. Anemic patients were more likely to be receiving diuretics (p
 0.0001) and have a lower mean corpuscular volume (p  0.0001), with a trend toward a higher New York
Heart Association functional class (p  0.06). During a median follow-up of 47 months, 55 patients died. Ane-
mic patients had a 3-fold higher mortality risk compared with nonanemic patients, even after propensity score
adjustment for clinical variables such as systemic ventricular function, renal impairment, and diuretic therapy
(adjusted hazard ratio: 3.00; 95% confidence interval: 1.46 to 6.13).
Conclusions Anemia is not uncommon in ACHD patients attending tertiary services and is associated with a 3-fold increased
risk of death. Screening for anemia should be part of the routine assessment of ACHD patients for risk stratifica-
tion and treatment when correctable causes are identified. (J Am Coll Cardiol 2009;54:2093–100) © 2009 by
the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.06.050a
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wnemia is common in acquired heart failure, relates to
unctional capacity, and, even when mild, is a strong
rognostic marker for survival (1–9). The pathogenesis of
rom the *Adult Congenital Heart Centre and Centre for Pulmonary Hypertension,
oyal Brompton Hospital, London, United Kingdom; †Department of Clinical
ardiology, National Heart and Lung Institute, Imperial College School of Medicine,
ondon, United Kingdom; and the ‡International Centre for Cardiocirculatory
ealth, St. Mary’s Hospital, London, United Kingdom. Dr. Dimopoulos has been
upported by the European Society of Cardiology. Dr. Giannakoulas is supported by
he Hellenic Heart Foundation, the DG Education & Culture—LLP Programme—
eonardo Da Vinci Mobility, and the Hellenic Cardiological Society. Dr. Karaoli was
upported by the European Union (DaVinci programme). Dr. Francis is supported by
he British Heart Foundation. The Royal Brompton Adult Congenital Heart
rogramme and the Department of Clinical Cardiology have received support from
he British Heart Foundation and the Clinical Research Committee, Royal Brompton
ospital, London.f
Manuscript received February 20, 2009; revised manuscript received May 28, 2009,
ccepted June 28, 2009.nemia in this setting is multifactorial; its prevalence in-
reases with age, chronic kidney disease, and clinical signs of
ongestive heart failure (10,11). Anemia has also been
eported in mildly symptomatic or even asymptomatic
atients, however, suggesting that its pathogenesis relates to
ther factors than just cardiac dysfunction (12). Impaired
rythropoietic secretion and neurohormonal activation, for
xample, seem to be important additional contributors to
he development of anemia in heart failure (13).
Even though chronic renal dysfunction and neurohor-
onal activation are commonly encountered in adults with
ongenital heart disease (ACHD) (14–18), limited data on
he prevalence of anemia across the spectrum of ACHD are
vailable at present (19). We hypothesized that anemia
ould be relatively common in ACHD and relate tounctional class and survival.
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Data were collected on all con-
secutive clinically stable noncya-
notic ACHD patients who had
hemoglobin concentration mea-
sured in our tertiary center be-
tween May 2001 and June 2006.
Cyanotic patients (including
those with Eisenmenger syn-
drome, where by definition, there
is right-to-left shunting) were
excluded to avoid bias deriving
rom the stimulant effect of chronic hypoxia on hemopoie-
is. Anemia was defined as hemoglobin concentration 13
/dl in males and 12 g/dl in females, according to the
orld Health Organization criteria (20). Mean corpus-
ular volume (MCV) and serum creatinine concentration
ere also recorded, when available, on the same date.
epeated measurements, other than the first, were ex-
luded from analysis. Measurements made after emer-
ency admissions or within 6 months after surgery,
atheter intervention, and/or major bleeding were also
xcluded from the analysis. Clinical data were acquired
rom patient records; specific congenital heart disease
iagnoses were previously verified by echocardiography,
ardiovascular magnetic resonance, and/or cardiac cath-
terization. Patients were classified into diagnostic
roups according to the underlying cardiac anatomy (21).
atients with more than 1 defect were classified according to
he prevalent lesion from a clinical and/or hemodynamic
oint of view. Systemic ventricular function from transtho-
acic echocardiograms within a year of blood sampling was
ecorded as a 3-level categorical variable: normal, mildly
mpaired, and moderately/severely impaired (14).
Survival status and time to death were obtained from the
ational Health Service computer system, linked to the
ational database held by the Office of National Statistics.
pproval by the local ethical committee of the Royal
rompton Hospital was obtained.
tatistical analysis. Numerical values are presented as
ean  SD, categorical variables as percentage of total.
omparisons between groups were performed using the
ilcoxon rank sum and the Kruskal-Wallis tests for con-
inuous variables and the Fisher exact test for categorical
ariables. Univariate logistic regression analysis was used to
ssess the relation between anemia and clinical and demo-
raphic parameters, followed by multivariate analysis in-
luding all parameters that were significant (2-sided p 
.05) on univariate analysis, to the multivariate model. Cox
egression analysis was used to assess the relation between
nemia and death. To account for differences between
nemic and nonanemic patients, propensity score matching
as used. Propensity scores were computed using logistic
egression, with anemia as the dependent variable and
Abbreviations
and Acronyms
ACHD  adults with
congenital heart disease
ccTGA  congenitally
corrected transposition of
great arteries
MCV  mean corpuscular
volume
NYHA  New York Heart
Associationaseline demographic and clinical variables as independent hariables: age, sex, functional class, previous palliative or
eparative surgery/sternotomy, systemic ventricular func-
ion, serum creatinine levels, MCV, and medication (diuret-
cs, beta-blockers, digoxin, angiotensin-converting enzyme
nhibitors/angiotensin receptor blockers, warfarin, and as-
irin) (18). Propensity scores were used to perform 5:1
earest neighbor matching (4 nonanemic to 1 anemic
atient) within a caliper of 0.05 SDs of the propensity score
R version 2.8.1, package “matchit”) (22). Balance was
erified by assessing standardized differences between
roups for all variables in the matched cohort. A target of
10% standardized difference for all variables was set and
btained. Univariable Cox regression was then used to
ompare mortality between anemic and nonanemic patients
n the matched cohort, thus accounting for baseline differ-
nces between groups while avoiding an over-fit of the Cox
odel. As a sensitivity analysis, regression adjustment using
ropensity score quartiles was also performed. Missing
alues were 10% for all variables (mean 1%, range 0% to
%). As propensity score matching requires complete data-
ets, missing data were imputed using multiple imputation
R version 2.8.1, package “Amelia,” which uses a
ootstrapping-based expectation-maximization algorithm)
22). Ten values for each missing cell in the data were imputed
o create 10 different “complete” datasets; models were then
stimated for each dataset (23). Cox analysis was then per-
ormed after propensity score matching and propensity score
egression adjustment using each of the 10 databases. Esti-
ates were averaged, and the hazard ratio (HR) of anemic
ersus nonanemic patients was computed. The variance of the
stimated log(HR) was calculated as the average of the esti-
ated variances from each dataset plus the sample variance in
oint estimates across datasets (18). Moreover, Kaplan-Meier
urvival curves were plotted, and the log-rank test was used for
omparison between groups. All p values were 2-sided, and p
0.05 was considered to indicate statistical significance.
nalyses were performed using R version 2.8.1. (22).
esults
atient population. Overall, 830 noncyanotic ACHD pa-
ients (mean age 36.5  15.0 years, 49.6% male) (Table 1)
ttending our tertiary center fulfilled inclusion criteria.
atients from all major ACHD diagnostic groups were
ncluded; 72% had undergone previous surgical repair. The
ajority of patients (72.2%) were asymptomatic at the time
f the study.
emoglobin concentration, hematocrit, and anemia.
ean hemoglobin concentration in noncyanotic ACHD
atients was 14.1  1.7 g/dl (Table 2); 13.1% of patients
ere anemic (Table 3). As expected, hemoglobin concen-
ration was higher in men compared with women (14.8 
.6 g/dl vs. 13.4  1.5 g/dl; p  0.0001) (Fig. 1). No sex
ifference, however, was found in the prevalence of anemia
12.1% in men vs. 14.1% in women, p  0.41). Mean
emoglobin concentration was within normal range for all
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November 24, 2009:2093–100 Anemia in Adults With Congenital Heart DiseaseCHD diagnostic groups and was lowest in patients with
ongenitally corrected transposition of great arteries
ccTGA) (13.3  2.1 g/dl). Patients with ccTGA had the
ighest prevalence of anemia (27.3%), followed by patients
ith Ebstein anomaly of the tricuspid valve (20.0%)
Fig. 2).
REDICTORS OF ANEMIA. Univariate predictors of anemia
ere a lower MCV (odds ratio [OR]: 1.89 per 10-fl
ecrease; 95% confidence interval [CI]: 1.37 to 2.61; p 
.0001), treatment with diuretics (OR: 2.66; 95% CI: 1.74
o 4.03; p  0.0001), and treatment with warfarin (OR:
.59; 95% CI: 1.01 to 2.50; p 0.046). In addition, a strong
rend for anemia among patients in New York Heart
ssociation (NYHA) functional class III or IV (OR: 1.86;
5% CI: 0.94 to 3.48; p  0.06) and in those with higher
reatinine concentration (OR: 1.50; 95% CI: 0.98 to 2.31;
 0.06) was also observed. MCV (adjusted OR: 1.98 per
emographic and Clinical Characteristics According to UnderlyingTable 1 Demographic and Clinical Characteristics According to
n (%) Age (yrs) Male
Atrial septal defect 144 (17.3) 45.0 17.5 36.8 72
Ventricular septal defect 44 (5.3) 32.0 11.6 45.5 79
Aortic coarctation 107 (12.9) 33.5 13.9 56.1 85
Valve/outflow tract disease 136 (16.4) 36.6 14.8 56.6 71
Atrioventricular septal defects 45 (5.4) 36.2 14.1 42.2 79
Repaired tetralogy of Fallot 120 (14.5) 36.4 12.8 56.7 65
Ebstein anomaly of the tricuspid 20 (2.4) 43.9 14.2 40.0 64
ccTGA 22 (2.7) 39.8 14.5 54.5 30
Mustard 37 (4.5) 29.9 7.1 51.4 73
Fontan 35 (4.2) 25.4 8.1 45.7 60
Complex 32 (3.9) 29.2 10.7 59.4 61
Other congenital defects 88 (10.6) 36.3 15.5 46.6 75
Total 830 (100) 36.5 15.0 49.6 72
alues are percentages unless otherwise indicated.
ccTGA  congenitally corrected transposition of great arteries; NYHA  New York Heart Associ
aboratory Values According to Specific ACHDiagnosisTable 2 Laboratory Values According to Specific ACHDDiagnosis
Hb
(g/dl)
MCV
(fl)
Creatinine
(mg/dl)
Atrial septal defects 13.9 1.5 89.6 7.4 0.92 0.33
Ventricular septal defect 14.1 1.5 88.5 5.4 0.93 0.22
Aortic coarctation 13.9 1.4 88.1 4.4 0.91 0.19
Valve/outflow tract disease 13.9 1.8 88.6 6.0 0.91 0.22
Atrioventricular septal defects 14.0 2.0 91.0 5.3 0.90 0.21
Repaired tetralogy of Fallot 14.5 1.5 88.9 5.7 1.03 0.79
Ebstein anomaly of the tricuspid 13.9 1.7 91.3 4.5 0.98 0.28
ccTGA 13.3 2.1 91.9 6.9 1.01 0.47
Mustard 14.8 1.7 89.3 4.5 0.93 0.19
Fontan 14.6 2.3 90.2 6.0 1.02 0.53
Complex 14.6 2.0 88.1 5.2 0.90 0.19
Other congenital defects 13.8 1.6 88.8 6.0 0.95 0.32
Total 14.1 1.7 89.1 5.9 0.94 0.40m
CHD  adults with congenital heart disease; ccTGA  congenitally corrected transposition of
reat arteries; Hb  hemoglobin; MCV  mean corpuscular volume.0-fl decrease; 95% CI: 1.43 to 2.75; p  0.0001) and
reatment with diuretics (adjusted OR: 2.86; 95% CI: 1.85
o 4.39; p 0.0001) were the only multivariate predictors of
nemia. Despite the clear association between MCV levels
nd anemia, only 25.7% of anemic patients were microcytic
MCV 84 fl).
To further investigate the relation between a low MCV,
n indirect marker of bleeding, and anemia, we performed a
ubanalysis in patients on warfarin therapy. Microcytosis
as found in 29.0% of anemic compared with 9.1% of
onanemic patients undergoing warfarin therapy. However,
2 of the 31 (71%) anemic patients on warfarin had no
icrocytosis.
emoglobin concentration and anemia as a predictor of
utcome. During a median follow-up of 47.3 months, 55
atients died. Overall mortality was 1.7% per year (95% CI:
.3% to 2.2%). The highest mortality was observed in the
cTGA group (10.0% per year; 95% CI: 4.0% to 20.7%),
ollowed by the Fontan population (5.3% per year; 95% CI:
.1% to 11.0%). Median time to death was 48.6 months,
nd median age at death was 36.3 years.
Anemic patients were at significantly higher risk of death
ompared with patients without anemia (5-year mortality of
7.7% vs. 6.0% in nonanemic patients; log-rank p  0.0001)
Fig. 3). On univariate Cox analysis, anemia was a strong
redictor of mortality (HR: 3.13; 95% CI: 1.77 to 5.55;
 0.0001) (Fig. 4). Other univariate predictors of death
ere a higher NYHA functional class; treatment with
iuretics, angiotensin-converting enzyme inhibitors or an-
iotensin receptor blockers, beta-blockers, digoxin, or war-
arin; a higher creatinine concentration; and moderate-
evere systemic ventricular dysfunction. On multivariable
nalysis including all univariable predictors, anemia re-
ained a predictor of outcome (adjusted HR: 2.26; 95% CI:
.12 to 4.52). After propensity-score analysis, anemia re-
osiserlying Diagnosis
A Functional Class Previous Surgery
Systemic Ventricular
Dysfunction
II III IV Palliation Repair Mild Moderate-Severe
19.7 7.6 0.0 0.0 41.7 2.1 1.4
13.6 6.8 0.0 6.8 70.5 17.1 2.4
8.5 5.7 0.0 0.0 71.0 2.8 5.7
21.5 6.6 0.0 0.0 83.8 12.5 4.7
17.9 2.6 0.0 6.7 74.4 7.1 0.0
22.9 11.0 0.9 43.3 100.0 12.8 2.6
21.4 14.3 0.0 0.0 60.0 5.3 0.0
50.0 10.0 10.0 13.6 22.7 14.3 38.1
23.3 3.3 0.0 27.0 100.0 36.1 22.2
26.7 6.7 6.7 61.8 100.0 37.9 6.9
26.9 11.5 0.0 37.5 65.6 3.6 10.7
17.9 7.1 0.0 9.1 54.5 8.5 9.8
19.7 7.4 0.7 13.5 71.9 10.5 5.9DiagnUnd
NYH
I
.7
.5
.8
.9
.5
.1
.3
.0
.3
.0
.5
.0
.2ained a strong predictor of outcome (HR: 3.00; 95% CI:
C*
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Anemia in Adults With Congenital Heart Disease November 24, 2009:2093–100omparison Between Anemic and Nonanemic PatientsTable 3 Comparison Between Anemic and Nonanemic Patients
Overall Anemic Nonanemic p Value*
n (%) 830 (100) 109 (13.1) 721 (86.9)
Age (yrs) 36.5 15.0 38.1 15.0 36.3 14.9 0.19
Sex (male, %) 49.6 45.9 50.2 0.41
NYHA functional class (%)
I 72.2 66.3 73.1 0.73
II 19.7 20.8 19.6 0.79
III 7.4 10.9 6.9 0.16
IV 0.7 2.0 0.5 0.27
Diuretics (%) 24.3 42.2 21.6 0.0001
Warfarin (%) 21.1 28.4 20.0 0.06
ACE-I/ARB (%) 26.9 28.4 26.6 0.73
Beta-blockers (%) 22.8 25.7 22.4 0.46
Aspirin (%) 16.1 14.7 16.3 0.78
Digoxin (%) 11.0 12.8 10.7 0.51
Previous palliation (%) 13.5 7.3 14.4 0.06
Previous repair (%) 71.9 70.6 72.1 0.84
Systemic ventricular dysfunction (%)
Mild 10.5 13.7 10.0 0.33
Moderate-severe 5.9 8.8 5.5 0.27
Mean cellular volume (fl) 89.1 6.0 87.0 9.1 89.4 5.2 0.005
Plasma creatinine (mg/dl) 0.94 0.39 1.02 0.85 0.92 0.27 0.16p value between patients with and without anemia.
ACE-I  angiotensin-converting enzyme inhibitor; ARB  angiotensin receptor blocker; NYHA  New York Heart Association.Figure 1 Hemoglobin Concentration Distribution
Distribution of hemoglobin concentration in adults with congenital heart disease according to sex.
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November 24, 2009:2093–100 Anemia in Adults With Congenital Heart Disease.46 to 6.13 by matching and HR: 2.83; 95% CI: 1.57 to
.10 by regression adjustment).
iscussion
nemia was relatively common in this young population of
oncyanotic ACHD patients. Low MCV and treatment
ith diuretics were significant predictors of anemia, sug-
esting a possible role of iron deficiency and of the heart
ailure syndrome in its pathogenesis. Anemic ACHD pa-
ients were at a 3-fold risk of death, even after adjustment
or functional class, systemic ventricular function, and other
stablished risk factors.
he prevalence of anemia in ACHD. The prevalence of
nemia in this ACHD population appears to be lower than
hat reported for acquired heart failure, even though re-
orted estimates of the prevalence of anemia in acquired
eart disease vary widely (ranging between 9% and 79%,
ccording to the characteristics of the population studied)
1–4,6–8). ACHD patients in our study were much
ounger than the average cohort of patients with ischemic
eart disease or heart failure and were, in their vast majority
Figure 2 Prevalence of Anemia
The prevalence of anemia in various adults with congenital heart disease diag-
nostic groups. ccTGA  congenitally corrected transposition of great arteries.72%), asymptomatic.he pathogenesis of anemia in congenital heart disease. The
tiology of anemia in ACHD is likely to be multifactorial
12). Patients in the ccTGA diagnostic subgroup, who had
he highest prevalence of anemia (27.3%), also had the
ighest prevalence of symptoms (70%) (Table 1) and the
ighest prevalence of systemic ventricular dysfunction, sug-
esting a possible role of ventricular dysfunction in patho-
enesis. However, a high prevalence of anemia was also
bserved in patients with Ebstein anomaly of the tricuspid
alve, a primarily right-sided lesion with resultant low
ystemic cardiac output. MCV and the use of diuretics were
ndependent predictors of anemia in the noncyanotic pop-
lation, suggesting that renal impairment, abnormal iron
etabolism, and circulatory congestion contribute indepen-
ently toward the occurrence of anemia in ACHD. Fur-
hermore, anemia in ACHD patients can occur as the result
f acute or chronic blood loss due to abnormal hemostasis,
ascular bleeding (arteriovenous malformations or collateral
essels), use of anticoagulants and antiplatelets, hemolysis
prosthetic valves, intracardiac patches, or conduits), inter-
ention, or surgery. The strong relation between anemia and
CV found in this study is in favor of iron deficiency being
predisposing factor for anemia. Although we have ex-
luded patients who had recent catheter interventions or
urgery to account for post-operative anemia (common), we
annot exclude that anemia is due to inadequate iron intake
dietary or due to malabsorption), although this, we specu-
ate, is unlikely in the noncyanotic ACHD patients (24).
espite the strong correlation between MCV, treatment
ith warfarin, and anemia, only a minority of patients from
he subgroup of patients undergoing warfarin therapy were
icrocytic, suggesting a multifactorial etiology of anemia in
his population.
Reduced hemopoiesis is another potential mechanism of
nemia in ACHD. Reduced erythropoietin production is
ssociated with renal dysfunction, which we have recently
hown to be common in ACHD (18). However, no significant
Figure 3 Unadjusted Mortality Curves
Unadjusted Kaplan-Meier mortality curves according to the presence of anemia.
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Anemia in Adults With Congenital Heart Disease November 24, 2009:2093–100elation was found between creatinine concentration and ane-
ia in the present study. “Anemia of chronic disease” is
nother plausible cause of anemia in ACHD patients. Acute or
hronic immune activation is the basis of anemia of chronic
isease, as cytokines and the reticuloendothelial system affect
ron homeostasis, erythropoietin production, and the life du-
ation of erythrocytes (10,18,25–28). Immune activation in-
reases hepcidin concentration, which interacts with intestinal
ron transport proteins such as ferroportin, and inhibits iron
bsorption (29,30). Elevated cytokine levels such as tumor
ecrosis factor-alpha have been reported in ACHD pa-
ients, especially in the presence of cyanosis and peripheral
dema (31–33). The strong relation between diuretic use
nd anemia underlines the importance of the heart failure
yndrome in the pathophysiology of ACHD (34).
he relation between anemia and outcome of ACHD
atients. The prognostic power of anemia may derive from
ts relation to disease severity and exercise capacity (4,6,11).
he oxygen-carrying capacity of the blood is, in fact, an
ssential component of the cardiorespiratory chain responsible
or providing peripheral tissues with oxygen adequate for their
etabolic needs. Anemia results in reduced oxygen-carrying
apacity and a premature shift to anaerobic metabolism during
xertion. Anemia may also precipitate heart failure and cause
eterioration in exercise capacity by increasing venous return
Figure 4 Univariate Predictors of Mortality
Univariate predictors of death: hazard ratio and 95% confidence interval. ACEi/ARB
enzyme inhibitor/angiotensin receptor blockers; NYHA  New York Heart Associatnd reducing oxygen delivery to the myocardium. However, phere was only a trend toward higher prevalence of anemia in
ore impaired patients. This may reflect the poor ability of
ubjective assessment of functional status in predicting true
unctional capacity, rather than a lack of relation between
nemia and exercise capacity. It has, in fact, been shown that
ubjective measures of functional status such as the NYHA
unctional classification tend to underestimate the degree of
mpairment in ACHD patients (21,34–36).
The prognostic power of anemia could also derive from its
stablished relation to renal dysfunction. Decreased renal
unction and anemia are risk factors for all-cause mortality in
atients with left ventricular dysfunction, especially when both
re present, and renal dysfunction is a strong predictor of
utcome in ACHD (1,2,6,8,11,18,37). However, anemia was
strong predictor of death even after adjustment for systemic
entricular function, functional class, and renal impairment.
he established relation between neurohormonal and cytokine
ctivation and anemia in acquired heart failure may also explain
he prognostic power of anemia in ACHD.
linical implications. In this population, anemia was a
trong and independent prognostic marker. Screening for
nemia should become part of the routine assessment of
CHD patients as a measure of risk stratification. Correctable
auses of anemia, such as bleeding, should always be sought
nd treated. Trials of administration of recombinant erythro-
giotensin-converting an
ion.oietin in anemic patients with acquired heart failure have been
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November 24, 2009:2093–100 Anemia in Adults With Congenital Heart Diseaseromising (38–40). Erythropoietin and iron administration
ave resulted in reduction of symptoms, improvement of
xercise tolerance, and reduced need for diuretics. Whether or
ot chronic treatment of anemia with iron supplementation
nd erythropoietin leads to an improvement in outcome in
CHD patients needs to be established.
tudy limitations. Cyanotic ACHD patients (including
hose with Eisenmenger syndrome) were excluded from this
tudy to avoid confounding from secondary erythrocytosis
nd the inherent difficulty of defining anemia in this
opulation. Increased hemoglobin levels in cyanotic patients
epresent an appropriate physiological adaptation to chron-
cally low oxygen saturations. Iron deficiency “relative ane-
ia” is frequent in cyanotic patients, but occurs at hemo-
lobin levels much higher than those of noncyanotic
ndividuals, and its diagnosis requires information in addi-
ion to mere hemoglobin concentration (e.g., transferrin
aturation and ferritin levels) (24,41–44). Thus, a uniform
efinition of anemia across the entire ACHD spectrum is
ot feasible.
Although not every single patient seen in our center
uring the study period underwent blood testing, this was
ore likely due to patient preference rather than physician
hoice. Our tertiary ACHD center manages patients from
ngland and Wales, and many of them opt to have their
lood tests locally. Thus, a selection bias cannot be ex-
luded. Furthermore, the case mix of ACHD diagnostic
ubgroups in our study, excluding the cyanotic patients, is
ery representative of ACHD tertiary work. Future, larger
rospective studies with longer follow-up and including
atients who are not under tertiary care may provide
dditional information on anemia mechanisms as well as its
rognostic value in ACHD patients in general and specific
CHD diagnostic subgroups in particular.
onclusions
nemia is not uncommon in ACHD patients attending
ertiary centers. Anemic ACHD patients have a 3-fold
ncreased mortality risk in the medium term. Screening for
nemia should be part of the routine assessment of ACHD
atients for risk stratification, and for treatment, when
orrectable causes are identified.
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